IU Health rethinks design of patient rooms
The health care system is making big changes, down to the smallest details, for the 864 patient rooms in the academic hospital system’s massive new downtown hospital.
Health Care & Life Sciences
Articles
Animal-health startup BiomEdit advances poultry antibody, lands $20M in funding, grants
BiomEdit said the disease it’s targeting, avian necrotic enteritis, causes an estimated $6 billion in annual losses worldwide.
Longtime Community Health CEO Bryan Mills to retire
Mills joined Community in 1985 when it was a single hospital. Today, it operates five acute-care hospitals (with a sixth in the works), a cardiovascular hospital, a recovery center, three rehabilitation hospitals and a freestanding behavioral health hospital.
‘Narrow’ health plans gain wider acceptance
Direct-to-employer health insurance plans, in which an employer contracts directly with a health care network for coverage, restrict provider choice but are generally less expensive for employers and employees.
IU School of Medicine opens new $230M education and research building
The school’s primary classroom and education facility is being moved from its longtime home on the Indianapolis campus to be closer to the new IU Health teaching hospital, set to open in 2027.
IU professor’s work leads to Alzheimer’s blood test
Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.
Lilly hosts Reddit ‘Ask Me Anything’ Q&A on blockbuster weight-loss drug Zepbound
Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk’s Wegovy.
FDA to offer faster drug reviews to companies promoting ‘national priorities’
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.
Lilly acquires cardiovascular genetic medicine company for up to $1.3B
Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.
Indianapolis-based startup leans on connections to treat brain diseases
Syndeio Biosciences sees burgeoning potential to treat mental health and cognitive conditions, including Alzheimer’s and depression, with therapies that target the almost countless minuscule brain synapses that give people the ability to think and function.
IU unveils architectural design plan for IU LAB at 16 Tech
The five-story, 150,000 square-foot building will be built next to the Herron School of Art and Design’s Eskenazi Fine Arts Center on Indiana Avenue in Indianapolis.
Power-lifting nurse helps Franciscan center focuses on prevention, wellness for cancer and cardiac disease
The Franciscan Healthy Living Center, which opened in 2020, is designed to help those who’ve been through cancer, heart disease, surgery or other serious conditions improve their health factors, including diet, fitness, sleep and mental health.
Lilly says weight loss pill has vast opportunity
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Reports: Lilly eyes Houston for new $5.9B manufacturing facility
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.
Indianapolis-based Prevounce Health on navigating tariff uncertainty
The med-tech company sources its products from a Chinese manufacturer that is one of very few in the world capable of producing cellular-connected medical devices.
Novo to sell Wegovy at $199 a month as copycat availability ends
On Thursday, pharmacies were supposed to stop making the copies of the medications that had become popular during shortages of the brand-name drugs.
Once-hyped IU Health People Mover fades into oblivion
IU Health’s People Mover is unusual—or it certainly was at the time it was conceived—because of its use of public right of way.
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.
Zimmer Biomet ‘cementless’ partial knee implant makes Indiana debut
The Zimmer Biomet Oxford Cementless Partial Knee System received FDA approval in November, although the implant has been used in more than 300,000 procedures outside the U.S.
UPDATE: Roche Diagnostics to invest up to $550M in Indianapolis, adding hundreds of local jobs
The Swiss pharmaceutical and diagnostics giant said the move will establish the Indianapolis-based Roche Diagnostics site as a hub for manufacturing of its continuous glucose monitoring system.